JP2013544244A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544244A5
JP2013544244A5 JP2013539093A JP2013539093A JP2013544244A5 JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5 JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
interleukin
inflammation
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544244A (ja
Filing date
Publication date
Priority claimed from CN201010551433.8A external-priority patent/CN102462837B/zh
Application filed filed Critical
Publication of JP2013544244A publication Critical patent/JP2013544244A/ja
Publication of JP2013544244A5 publication Critical patent/JP2013544244A5/ja
Pending legal-status Critical Current

Links

JP2013539093A 2010-11-19 2011-11-09 抗炎症組成物 Pending JP2013544244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010551433.8 2010-11-19
CN201010551433.8A CN102462837B (zh) 2010-11-19 2010-11-19 抗炎组合物
PCT/AU2011/001446 WO2012065212A1 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
JP2013544244A JP2013544244A (ja) 2013-12-12
JP2013544244A5 true JP2013544244A5 (https=) 2014-12-25

Family

ID=46067145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539093A Pending JP2013544244A (ja) 2010-11-19 2011-11-09 抗炎症組成物

Country Status (12)

Country Link
US (1) US9289493B2 (https=)
EP (1) EP2640411B1 (https=)
JP (1) JP2013544244A (https=)
KR (1) KR101989201B1 (https=)
CN (1) CN102462837B (https=)
AU (1) AU2011331901B2 (https=)
CA (1) CA2817996C (https=)
DK (1) DK2640411T3 (https=)
MX (1) MX348794B (https=)
MY (1) MY174797A (https=)
RU (1) RU2627451C9 (https=)
WO (1) WO2012065212A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
KR102220006B1 (ko) * 2011-03-11 2021-02-24 아시스땅스 퍼블리끄-오삐또 드 빠리 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 il­2 의 용도
NL2009794C2 (nl) 2012-11-13 2014-05-14 Hevorma B V Groei-inrichting voor gewas, gebruik van een dergelijke inrichting, en een reeks groei-inrichtingen.
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
ES2972640T3 (es) * 2015-02-25 2024-06-13 Outsense Diagnostics Ltd Análisis de emisiones corporales
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7169591B2 (ja) * 2016-09-15 2022-11-11 スキンテック ライフ サイエンス リミテッド 皮膚疾患の処置のためのdimの舌下又は頬側の投与
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
WO2021201615A1 (ko) 2020-03-31 2021-10-07 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0545913B1 (en) * 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
DK0462305T3 (da) * 1990-06-21 1995-04-24 Huland Edith Anvendelse af cytokinholdige aerosoler såvel som cytokholdige aerosoler i sig selv
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
JP4023863B2 (ja) 1997-03-13 2007-12-19 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Il−6を含む血清尿酸値低下剤
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
WO2000037096A2 (en) * 1998-12-22 2000-06-29 Schering Corporation Treatment of hepatitis c virus infections with interleukin-10
CA2388562C (en) 1999-09-09 2014-07-22 Schering Corporation Mammalian cytokines; related reagents and methods
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
BR0314356A (pt) 2002-09-16 2005-07-19 Wyeth Corp Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
WO2008109953A1 (en) 2007-03-14 2008-09-18 Sai Ying Ko Method for treating cancer via the mucosal administration of interleukin
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途

Similar Documents

Publication Publication Date Title
JP2013544244A5 (https=)
RU2013127793A (ru) Противовоспалительные композиции
Lautenschläger et al. Drug delivery strategies in the therapy of inflammatory bowel disease
Jacques et al. The role of IL‐1 and IL‐1Ra in joint inflammation and cartilage degradation
JP2016523862A5 (https=)
EP2011487A3 (en) Pharmaceutical compositions for gastroinetestinal drug delivery
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
JP2014526503A5 (https=)
JP2013510123A5 (https=)
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
CN102014868B (zh) 含有棕榈酰乙醇酰胺和硬脂酰乙醇酰胺的药物制剂
AR095372A1 (es) Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer
JP2018505158A5 (https=)
JP2010535767A5 (https=)
JP2014523906A5 (https=)
JP2009544690A5 (https=)
JP2022504181A5 (https=)
JP2011157375A5 (https=)
JP2010500284A5 (https=)
JP2009502805A5 (https=)
JP2005512946A5 (https=)
Li et al. Obesity: Next game changer of allergic airway diseases?
JP2008516909A5 (https=)
JP2008533079A5 (https=)
CN103040805A (zh) 辛夷脂素的医药用途